- Home
- DCOMP vs DMAC Comparison
DCOMP vs DMAC Comparison
Compare DCOMP & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOMP
- DMAC
- Stock Information
- Founded
- DCOMP N/A
- DMAC 2000
- Country
- DCOMP United States
- DMAC United States
- Employees
- DCOMP 887
- DMAC N/A
- Industry
- DCOMP Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DCOMP Finance
- DMAC Health Care
- Exchange
- DCOMP Nasdaq
- DMAC Nasdaq
- Market Cap
- DCOMP N/A
- DMAC 178.0M
- IPO Year
- DCOMP N/A
- DMAC N/A
- Fundamental
- Price
- DCOMP $19.10
- DMAC $3.57
- Analyst Decision
- DCOMP
- DMAC Strong Buy
- Analyst Count
- DCOMP 0
- DMAC 2
- Target Price
- DCOMP N/A
- DMAC $8.00
- AVG Volume (30 Days)
- DCOMP N/A
- DMAC 307.0K
- Earning Date
- DCOMP N/A
- DMAC 08-06-2025
- Dividend Yield
- DCOMP N/A
- DMAC N/A
- EPS Growth
- DCOMP N/A
- DMAC N/A
- EPS
- DCOMP N/A
- DMAC N/A
- Revenue
- DCOMP N/A
- DMAC N/A
- Revenue This Year
- DCOMP N/A
- DMAC N/A
- Revenue Next Year
- DCOMP N/A
- DMAC N/A
- P/E Ratio
- DCOMP N/A
- DMAC N/A
- Revenue Growth
- DCOMP N/A
- DMAC N/A
- 52 Week Low
- DCOMP N/A
- DMAC $2.72
- 52 Week High
- DCOMP N/A
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- DCOMP 67.07
- DMAC 40.50
- Support Level
- DCOMP $17.90
- DMAC $3.70
- Resistance Level
- DCOMP $19.40
- DMAC $3.99
- Average True Range (ATR)
- DCOMP 0.39
- DMAC 0.31
- MACD
- DCOMP 0.17
- DMAC -0.01
- Stochastic Oscillator
- DCOMP 83.83
- DMAC 13.67
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.